Aclaris Therapeutics ACRS Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's other income (expense)?
- Aclaris Therapeutics (ACRS) reported other income (expense) of $2.37M in Q1 2026.
- How has Aclaris Therapeutics's other income (expense) changed year-over-year?
- Aclaris Therapeutics's other income (expense) decreased by 21.0% year-over-year, from $3M to $2.37M.
- What is the long-term trend for Aclaris Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's other income (expense) has grown at a 74.6% compound annual growth rate (CAGR), from -$1.23M to $11.45M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.